Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme
- 1 March 2004
- journal article
- clinical trial
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 67 (1/2) , 191-200
- https://doi.org/10.1023/b:neon.0000021803.01170.03
Abstract
Objectives:Glioblastoma multiforme (GBM) may potentially be responsive to antiangiogenic therapies as these tumors are highly vascularized and overexpress angiogenic factors. Thalidomide exhibits...Keywords
This publication has 27 references indexed in Scilit:
- A Boost for Tumor StarvationScience, 2003
- A phase II study of extended low-dose temozolomide in recurrent malignant gliomasNeuro-Oncology, 2002
- A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survivalJournal of Neurosurgery, 2001
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Preoperative anaplastic glioma tumor volume effects on patient survivalJournal of Surgical Oncology, 1999
- Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcomeJournal of Neurosurgery, 1999
- Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective studyPublished by Elsevier ,1997
- The charing cross hospital experience with temozolomide in patients with gliomasEuropean Journal Of Cancer, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivoNature, 1992